CALR and neoplasm: In a C57BL/6 mouse model, intravenous injection of 200 μg rCRT +/− MCA‐205 fibrosarcoma‐derived cells treated with 300 μM oxaliplatin, or MTX (4 μM) inhibited selective phagocytosis of CRT‐exposing tumour cells both in vitro and in vivo, but not bacteria, demonstrating the phagocytic pathway in general is not inhibited by soluble CRT, but the uptake of tumour cells by DCs is inhibited.69